5-Chloro-3-phenyl-1,2,4-oxadiazole → N-Cyclopropyl-N-[3-methyl-1-(3-phenyl-[1,2,4]oxadiazol-5-yl)-piperidin-4-yl]-4-oxazol-5-yl-benzamide
反応式
[CH:1]1([N:4]([CH:18]2[CH2:23][CH2:22][NH:21][CH2:20][CH:19]2[CH3:24])[C:5](=[O:17])[C:6]2[CH:11]=[CH:10][C:9]([C:12]3[O:16][CH:15]=[N:14][CH:13]=3)=[CH:8][CH:7]=2)[CH2:3][CH2:2]1.Cl[C:26]1[O:30][N:29]=[C:28]([C:31]2[CH:36]=[CH:35][CH:34]=[CH:33][CH:32]=2)[N:27]=1>CN1CCCC1=O>[CH:1]1([N:4]([CH:18]2[CH2:23][CH2:22][N:21]([C:26]3[O:30][N:29]=[C:28]([C:31]4[CH:36]=[CH:35][CH:34]=[CH:33][CH:32]=4)[N:27]=3)[CH2:20][CH:19]2[CH3:24])[C:5](=[O:17])[C:6]2[CH:7]=[CH:8][C:9]([C:12]3[O:16][CH:15]=[N:14][CH:13]=3)=[CH:10][CH:11]=2)[CH2:3][CH2:2]1参加物
4
実験手順
The title compound is prepared from N-cyclopropyl-N-(3-methyl-piperidin-4-yl)-4-oxazol-5-yl-benzamide and 5-chloro-3-phenyl-[1,2,4]oxadiazole following a procedure analogous to that described in Example 19 using N-methylpyrrolidinone as solvent. LC (method 3): tR=2.01 min; Mass spectrum (ESI+): m/z=470 [M+H]+.